Department of Biological Sciences, KAIST, Daejeon, Republic of Korea.
Biotechnol Bioeng. 2024 Mar;121(3):931-941. doi: 10.1002/bit.28611. Epub 2023 Nov 28.
Histone deacetylase inhibitors (iHDACs) have been extensively studied as enhancers of therapeutic protein production in recombinant Chinese hamster ovary (CHO) (rCHO) cell cultures. However, the addition of iHDACs reduces the viable cell concentration (VCC) in rCHO cell cultures, thereby reducing their potential to enhance therapeutic protein production. To mitigate the negative effects of iHDACs on VCC, screening using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-based single-gene knockout (KO) library in rCHO cells was performed in the presence of CI994, a member of iHDACs, and 10 potential KO genes that enhanced the VCC of CI994-treated rCHO cells were identified. Among these, Bcor was validated as a promising KO target that improved VCC without negatively affecting the specific productivity in the presence of CI994. Bcor KO increased the VCC and therapeutic protein concentrations in both batch and fed-batch cultures in the presence of CI994. Taken together, these findings highlight the potential of the whole-genome CRISPR/Cas9-based single-gene KO cell library to identify KO target genes for the development of iHDAC-resistant rCHO cells for enhanced therapeutic protein production.
组蛋白去乙酰化酶抑制剂(iHDACs)已被广泛研究作为增强重组中国仓鼠卵巢(rCHO)细胞培养物中治疗性蛋白生产的试剂。然而,添加 iHDACs 会降低 rCHO 细胞培养物中的活细胞浓度(VCC),从而降低其增强治疗性蛋白生产的潜力。为了减轻 iHDACs 对 VCC 的负面影响,在存在 iHDACs 成员 CI994 的情况下,使用基于成簇规律间隔短回文重复(CRISPR)/CRISPR 相关蛋白 9(Cas9)的单基因敲除(KO)文库在 rCHO 细胞中进行了筛选,鉴定出 10 个潜在的 KO 基因,这些基因增强了 CI994 处理的 rCHO 细胞的 VCC。在这些基因中,Bcor 被验证为一个有前途的 KO 靶点,它在存在 CI994 的情况下提高了 VCC 而不影响特异性生产率。Bcor KO 在 CI994 存在的情况下,无论是在批式培养还是补料分批培养中,均提高了 VCC 和治疗性蛋白的浓度。总之,这些发现强调了全基因组 CRISPR/Cas9 基于单基因 KO 细胞文库的潜力,可以鉴定 KO 靶基因,用于开发耐 iHDAC 的 rCHO 细胞,以增强治疗性蛋白的生产。